Introduction. Warfarin remains the preferred oral anticoagulant for the treatment of venous thromboembolism (VTE) in patients with advanced chronic kidney disease (CKD). Although the direct oral anticoagulants (DOACs) have become preferred for treatment of VTE in the general population. patients with advanced CKD were excluded from the landmark trials. https://www.roneverhart.com/5-15P-ANGLE-PLUG-B-W-HUBBELL-HBL5266CA/